To improve human health by speeding up research processes and reducing cost in scientific research and development of therapeutic drugs, vaccines and diagnostic products.
To become a leading supplier of biological research reagents with high quality.
To provide superior quality CRO services to the global life science and bio-tech community.
cDNA clones and qPCR primers
Top pharmaceutical and bio-tech companies
Universities and Research Institutions (CDC, NIH, etc.)
Hospitals and Medical centers
20+ staff with US/EU education
36% staff with Master or PhD degree
Management Team with extensive working experience in large Pharmas
December,2016 Sino Biological Inc.moved into newly- built office building.
September,2016 The 2rd International Forum of Young Life Scientists (IFYLS) BDA was hosted by Beijing Economic-Technological Development Area (BDA), which organized by Sino Biological Inc. and held in Zhaolin Grand Hotel Beijing.
September,2015 The 1st International Forum of Young Life Scientists (IFYLS) BDA was hosted by Beijing Economic-Technological Development Area (BDA), which organized by Sino Biological Inc. and held in Beijing Jin Jiang Fu Juan Hotel.
February, 2014: Complete development and production of proteins of Ebola virus.
April, 2013: Spent only 12 days to complete development and production of recombinant HA&NA proteins of H7N9 Avian Influenza virus.
July, 2012: Over 12000 products in our catalogue, including 2500+ protein products, 2300+ antibody products, sold to more than 7000 labs in 70+ countries in the world. The only bio-tech enterprise to receive the title of “Model Enterprise of Modern Service Innovation and Development" awarded by Ministry of Science and Technology of China.
August, 2012: Life Technologies was officially announced as the global partner of Sino Biological Inc.
December, 2012: Finished development and production of recombinant spike and capsid proteins of MERS-CoV virus within 50 days after public release of the virus gene sequence.
January, 2011: Provided services to the top ten global pharmaceutical companies.
April, 2011: Protein products exceeded 1700, antibody products >1000, including various detection antibodies in applications such as FCS, IHC, and enzyme/fluorescence conjugated antibodies.
April, 2010: Independently developed the second generation of rabbit monoclonal antibody technology, a leading technology in the world. Established ELISA kit production platform. Awarded as the G20 member (Beijing Biomedical Industry Spanning Development Project). Obtained ISO9001 quality certificate.
April, 2009: Established three recombinant protein production platforms and one antibody production platform. The lab area was expanded to 5000 square meters.
April, 2008: Launched the first batch of recombinant protein products, developed and manufactured in-house. Honored as Beijing High-Tech Enterprise.
January, 2007: Founded in Beijing.